Evidence map›Paper›PMID 30174244›Full record

Observational studyPediatric neurology2018

Infantile Spasms of Unknown Cause: Predictors of Outcome and Genotype-Phenotype Correlation.

Christopher J Yuskaitis, Maura R Z Ruzhnikov, Katherine B Howell, I Elaine Allen, Kush Kapur, Dennis J Dlugos, Ingrid E Scheffer, Annapurna Poduri, Elliott H Sherr

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Pediatric neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Electroclinical Features of Infantile Epileptic Spasms Syndrome.Annals of Indian Academy of Neurology · 2024
    Article
  10. Article
  11. Article
  12. Steps to Improve Precision Medicine in Epilepsy.Molecular diagnosis & therapy · 2023
    Article
  13. Article
  14. Article
  15. Case report:Frontiers in neurology · 2023
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Christopher J YuskaitisDepartment of Neurology and Division of Epilepsy, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts.
Maura R Z RuzhnikovDivision of Medical Genetics and Department of Pediatrics, Stanford University, Stanford, California.
Katherine B HowellDepartment of Neurology, Royal Children's Hospital, Parkville, Victoria, Australia.
I Elaine AllenDepartment of Epidemiology and Biostatistics/UCSF, University of California San Francisco, San Francisco, California.
Kush KapurDepartment of Neurology and Division of Epilepsy, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts.
Dennis J DlugosThe Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Ingrid E SchefferEpilepsy Research Centre, Austin Health, University of Melbourne, Melbourne, Victoria, Australia.
Annapurna PoduriDepartment of Neurology and Division of Epilepsy, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts.
Elliott H SherrDepartments of Neurology and Pediatrics, University of California San Francisco, San Francisco, California. Electronic address: SherrE@neuropeds.ucsf.edu.edu.

Funding

Impact of Initial Therapy and Response on Long Term Outcome in Children with CAEU01NS045911 · NINDS · CINCINNATI CHILDRENS HOSP MED CTR · PI GLAUSER, TRACY A · 2003 to 2013
$31.1M
The Epilepsy Phenome/ Genome Project (EPGP)U01NS053998 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LOWENSTEIN, DANIEL H · 2007 to 2013
$26.4M
De novo copy number variation and gene discovery in human brain malformationsR01NS058721 · NINDS · UNIVERSITY OF CHICAGO · PI ARGILLI, EMANUELA · 2008 to 2025
$10.9M
CH/BIDMC/Harvard Medical School Neurology Resident Research Education Program Competing RenewalR25NS070682 · NINDS · BOSTON CHILDREN'S HOSPITAL · PI PODURI, ANNAPURNA, SAPER, CLIFFORD B · 2010 to 2023
$4.5M
2 of 7 EPI4K - Phenotyping Clinical Informatics Core U01NS077276 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LOWENSTEIN, DANIEL H · 2011 to 2015
$3.1M
Multi-Institutional Pediatric Epilepsy Decision SupportR01LM011124 · NLM · CINCINNATI CHILDRENS HOSP MED CTR · PI PESTIAN, JOHN P · 2011 to 2013
$955k
Genetics of Familial Epilepsy SyndromesK23NS069784 · NINDS · BOSTON CHILDREN'S HOSPITAL · PI PODURI, ANNAPURNA · 2010 to 2014
$901k
4 of 7: Epi4K: Epileptic Encephalopathies ProjectU01NS077364 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SHERR, ELLIOTT · 2011 to 2013
$827k
NINDS NIH HHS K23 NS069784NINDS NIH HHS R01 NS058721NINDS NIH HHS R25 NS070682NINDS NIH HHS U01 NS045911NINDS NIH HHS U01 NS053998NINDS NIH HHS U01 NS077276NINDS NIH HHS U01 NS077364NLM NIH HHS R01 LM011124
6 · The paper itself

Abstract

backgroundNo large-scale studies have specifically evaluated the outcomes of infantile spasms (IS) of unknown cause, previously known as cryptogenic or idiopathic. The Epilepsy Phenome/Genome Project aimed to characterize IS of unknown cause by phenotype and genotype analysis.

methodsWe undertook a retrospective multicenter observational cohort of 133 individuals within the Epilepsy Phenome/Genome Project database met criteria for IS of unknown cause with at least six months of follow-up data. Clinical medical records, imaging, and electroencephalography were examined.

resultsNormal development occurred in only 15% of IS of unknown cause. The majority (85%) had clinically documented developmental delay (15% mild, 20% moderate, and 50% severe) at last assessment (median 2.7 years; interquartile interval 1.71-6.25 years). Predictors of positive developmental outcomes included no delay prior to IS (P < 0.001), older age of IS onset (median six months old), and resolution of IS after initial treatment (P < 0.001). Additional seizures after IS occurred in 67%, with predictors being seizures prior to IS (P = 0.018), earlier age of IS onset (median five months old), and refractory IS (P = 0.008). On a research basis, whole exome sequencing identified 15% with de novo variants in known epilepsy genes. Individuals with a genetic finding were more likely to have poor developmental outcomes (P = 0.035).

conclusionsThe current study highlights the predominately unfavorable developmental outcomes and that subsequent seizures are common in children with IS of unknown cause. Ongoing genetic evaluation of IS of seemingly unknown cause is likely to yield a diagnosis and provide valuable prognostic information.

Indexed as

Age of OnsetChildChild DevelopmentChild, PreschoolDevelopmental DisabilitiesExome SequencingFemaleHumansInfantMalePhenotypePrognosisRetrospective StudiesSpasms, InfantileCryptogenic infantile spasmsDevelopmental outcomesEpilepsyEpilepsy geneticsEpileptic encephalopathyGenotype-phenotypeInfantile spasmsSeizures

Identifiers

PMID30174244
PMCPMC8188823

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.